Rhabdomyolysis secondary to quetiapine

Abstract

Quetiapine is one of the drugs used most in current Psychiatry due to its therapeutic efficiency and clinical safety. We report the case of a 26-year-old male patient with severe mental retardation due to Y-chromosome partial deletion who initiated treatment with quetiapine for the control of his aggressiveness, and who developed severe rhabdomyolysis two weeks later. In spite of the confirmed clinical safety of quetiapine, doctors must monitor the appearance of rare but serious adverse effects as that presented in this clinical case.